MedPath

Effect of Inhalation Sedation Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome Course

Phase 4
Conditions
ARDS
Interventions
Drug: Inhalation Sedation
Drug: Intravenous Sedation
Registration Number
NCT04014218
Lead Sponsor
Moscow Regional Research and Clinical Institute (MONIKI)
Brief Summary

Investigation of effect of inhalation sedation by administration of Sevoflurane compared with Propofol on the moderate acute respiratory distress syndrome course in mechanically ventilated patients with sepsis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • sepsis
  • ARDS
  • P/F Ratio 100-250
  • start of mechanical ventilation
Exclusion Criteria
  • pregnancy
  • concomitant oncological disease
  • prior psychological impairment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Inhalation sedationInhalation Sedation-
PropofolIntravenous Sedation-
Primary Outcome Measures
NameTimeMethod
mortality28 days after ICU admission

28 days and in-hospital mortality

ICU Length of stay (LOS)45 days after ICU admission

Length of stay in ICU

Length of mechanical ventilation (LMV)45 days after ICU admission

Length of mechanical ventilation

Secondary Outcome Measures
NameTimeMethod
event of RRT28 days after ICU admission

event of Renal Replacement Therapy

MACCE28 days after ICU admission

Major Adverse Cardiac and Cerebrovascular Event

P/F Ratio45 days after ICU admission

minimal pO2/FiO2

Delirium5 days after ICU admission

onset and duration of delirium

Trial Locations

Locations (1)

Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy

🇷🇺

Moscow, Russian Federation

Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
🇷🇺Moscow, Russian Federation
Valery V Likhvantsev, Professor
Contact
+7 (903) 623-59-82
lik0704@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.